Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To compare the efficacy and tolerability of initial low doses to those of the standard initial dose of 24mg in patients with differentiated thyroid cancer.

Next Previous
X
Search
Trial Profile

To compare the efficacy and tolerability of initial low doses to those of the standard initial dose of 24mg in patients with differentiated thyroid cancer.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 08 Apr 2019 New trial record
    • 01 Mar 2019 Results published in the Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top